Creation of a low-risk reference group and reference interval of fasting venous plasma glucose

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 7, 2004, Pages 817-823

  Jørgensen, Lone G M ^a   Brandslund, Ivan ^a   Petersen, Per Hyltoft ^b   Stahl, Marta ^a   de Fine Olivarius, Niels ^c  

^a LILLEBAELT HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diabetes; Fasting venous plasma glucose; Normal distribution; Reference subjects; Reference values

Indexed keywords

GLUCOSE;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; NORMAL DISTRIBUTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

BLOOD GLUCOSE; DIABETES MELLITUS; FASTING; HUMANS; REFERENCE VALUES; RISK; SAMPLING STUDIES; STATISTICAL DISTRIBUTIONS;

EID: 4344601733     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.135     Document Type: Article

References (22)

1. ISO. Medical laboratories - particular requirements for quality and competence. ISO 15189. Geneva: ISO, 2003.
2. Commission of the European Communities. Proposal for a Directive of the European Parliament and the Council on measuring instruments. COM(2000) 0566.
3. Commission of the European Communities. Directive of the European Parliament and the Council on measuring instruments. COM(2002) 0037 final.
4. Henny J, Petitclerc C, Fuentes-Arderiu X, Hyltoft Petersen P, Queralto JM, Schiele F, et al. Need for revisiting the concept of reference values. Clin Chem Lab Med 2000;38:589-95
5. Solberg HE. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987;25:645-56.
6. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Standards for reporting of diagnostic accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Biochem 2003;36:2-7.
7. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Graig WY. Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Analysis 1998;12:363-70.
8. Kenny D, Fraser CG, Hyltoft Petersen P, Kallner. Consensus agreement. Scand J Clin Lab Invest 1999;59:585.
9. Magid E. Minimal requirements for test evaluation. Scand J Clin Lab Invest 1997;57 Suppl 227:90-4.
10. Jørgensen LGM, Stahl M, Brandslund I, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. The plasma glucose reference interval in a low-risk population. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus II. Scand J Clin Lab Invest 2001;61:181-90.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
12. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complication trial. Diabetes 1995;44:969-83.
13. UK Prospective Diabetes study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
14. Stahl M, Jørgensen LGM, Hyltoft Petersen P, Brandslund I, de Fine Olivarius N, Borch-Johnsen K. Optimization of preanalytical conditions and analysis of plasma glucose. The impact of the new WHO and ADA recommendations on the diagnosis of diabetes mellitus I. Scand J Clin Lab Invest 2001;61:169-80.
15. Hyltoft Petersen P, Blaabjerg O, Andersen M, Jørgensen LGM, Schousboe K, Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chem Lab Med 2004;42:715-724.
16. Lahti A, Hyltoft Petersen P, Boyd JC, Fraser CG, Jørgensen N. Objective criteria for partitioning Gaussian-distributed reference values into subgroups. Clin Chem 2002;48:338-52.
17. Gowans EMS, Hyltoft Petersen P, Blaabjerg O, Horder M. Analytical goals for the acceptance of common reference intervals for laboratories throughout a geographical area. Scand J Clin Lab Invest 1988;48:757-64.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committtee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
19. Hyltoft Petersen P, Brandslund I, Jørgensen LGM, Stahl M, de Fine Olivarius N, Borch-Johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glucose as basis for analytical quality specifications for the diagnosis of diabetes. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus diabetes III. Scand J Clin Lab Invest 2001;61:191-204.
20. Altman DG, Kenneth F, Moher D, Egger M, Davidoff F, Elbourne D, et al. for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Mad 2001;134:663-94.
21. Weiss NS, Rossing MA. Healthy screened bias in epidemiologic studies of cancer incidence. Epidemiology 1996;7:319-22.
22. Jones A, Cronin PA, Bowen M. Comparison of risk factors for coronary heart disease among attenders and non-attenders at a screening programme. Br J Gen Pract 1993;43:375-7.